Allspring Global Investments Holdings LLC Buys Shares of 191,577 Emergent BioSolutions Inc. (NYSE:EBS)

Allspring Global Investments Holdings LLC acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 191,577 shares of the biopharmaceutical company's stock, valued at approximately $1,831,000. Allspring Global Investments Holdings LLC owned 0.35% of Emergent BioSolutions at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in EBS. Stifel Financial Corp acquired a new stake in Emergent BioSolutions during the third quarter worth approximately $96,000. FORA Capital LLC bought a new position in Emergent BioSolutions during the 3rd quarter worth $103,000. Hilltop Holdings Inc. raised its holdings in Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company's stock worth $1,430,000 after purchasing an additional 12,515 shares during the last quarter. FMR LLC boosted its holdings in shares of Emergent BioSolutions by 12.6% during the 3rd quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company's stock worth $1,078,000 after buying an additional 14,446 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Emergent BioSolutions during the third quarter worth approximately $141,000. Institutional investors and hedge funds own 78.40% of the company's stock.

Emergent BioSolutions Trading Down 0.4 %

EBS stock traded down $0.03 during mid-day trading on Wednesday, reaching $7.18. 295,363 shares of the stock traded hands, compared to its average volume of 1,029,618. Emergent BioSolutions Inc. has a one year low of $1.82 and a one year high of $15.10. The stock has a market capitalization of $389.20 million, a PE ratio of -1.75 and a beta of 1.62. The business has a 50-day moving average price of $9.59 and a two-hundred day moving average price of $9.08. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EBS. StockNews.com upgraded shares of Emergent BioSolutions from a "hold" rating to a "buy" rating in a research note on Monday, February 17th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday, January 21st. Finally, Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.